Myelodysplastic syndrome : prognostic factors

The prognostic evaluation of myelodysplastic syndromes has evolved considerably over time, both due to the evolution of diagnostic classifications and the improvement in the prediction of the outcome. Many prognostic scores that have been developed over time take into account number and depth of blood cytopenias, as well bone marrow blast, cytogenetic, and more recently, molecular mutations. All these variables have been grouped together in IPSS-M score since 2022, which should quickly become a reference for the prognostic evaluation of MDS, as soon as molecular information is available for the patient.

Automated summary

The prognostic evaluation of myelodysplastic syndromes has undergone significant changes over time, and the IPSS-M score has become a reference for the prognosis of MDS.